Sayed Mehdi Hussain Hamadani MD

PubMed

• 26 citations
  Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting.
  Guru Subramanian Guru Murthy, Parameswaran Hari, Aniko Szabo, Marcelo C. Pasquini, Ravi Narra
  Biology of Blood and Marrow Transplantation. 2019-04-01
• 95 citations
  Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Rese...
  Carla Casulo, Jonathan W. Friedberg, Kwang Woo Ahn, Christopher R. Flowers, Alyssa DiGilio
  Biology of Blood and Marrow Transplantation. 2018-06-01
• 8 citations
  Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma
  Narendranath Epperla, Kwang Woo Ahn, Philippe Armand, Samantha Jaglowski, Sairah Ahmed
  Biology of Blood and Marrow Transplantation. 2018-01-01

Abstracts/Posters

• Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Population Level Outcomes of Chronic Lymphocytic Leukemia in the Era of Targeted Agents- Analysis of Surveillance Epidemiology and End Results (SEER) Database
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Making Progress in Graft-Versus-Host Disease Prophylaxis and Microbiome Analysis in the Blood and Marrow Transplant Clinical Trials Network: Progress III (1703)/MI-Imm...
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0406
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD+ AML
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Population Level Outcomes of Chronic Lymphocytic Leukemia in the Era of Targeted Agents- Analysis of Surveillance Epidemiology and End Results (SEER) Database
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Does Addition of Rituximab (R) to BEAM Conditioning Improve Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Tr...
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refra...
  Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lym... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018